These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19943335)

  • 21. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence.
    Teschke R; Qiu SX; Xuan TD; Lebot V
    Phytother Res; 2011 Sep; 25(9):1263-74. PubMed ID: 21442674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.).
    Anke J; Ramzan I
    J Ethnopharmacol; 2004 Aug; 93(2-3):153-60. PubMed ID: 15234747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(47):1065-7. PubMed ID: 12500906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kava hepatotoxicity.
    Russmann S; Lauterburg BH; Helbling A
    Ann Intern Med; 2001 Jul; 135(1):68-9. PubMed ID: 11434754
    [No Abstract]   [Full Text] [Related]  

  • 25. Tradition and toxicity: evidential cultures in the kava safety debate.
    Baker JD
    Soc Stud Sci; 2011 Jun; 41(3):361-84. PubMed ID: 21879526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward?
    Sarris J; Teschke R; Stough C; Scholey A; Schweitzer I
    Planta Med; 2011 Jan; 77(2):107-10. PubMed ID: 20814850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are mould hepatotoxins responsible for kava hepatotoxicity?
    Rowe A; Ramzan I
    Phytother Res; 2012 Nov; 26(11):1768-70. PubMed ID: 22319018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is kava alcohol?: The myths and the facts.
    Aporosa SA
    Pac Health Dialog; 2011 Mar; 17(1):157-64. PubMed ID: 23008981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.
    Gurley BJ; Gardner SF; Hubbard MA; Williams DK; Gentry WB; Khan IA; Shah A
    Clin Pharmacol Ther; 2005 May; 77(5):415-26. PubMed ID: 15900287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kava: herbal panacea or liver poison?
    Moulds RF; Malani J
    Med J Aust; 2003 May; 178(9):451-3. PubMed ID: 12720513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis induced by Kava (Piper methysticum rhizoma).
    Stickel F; Baumüller HM; Seitz K; Vasilakis D; Seitz G; Seitz HK; Schuppan D
    J Hepatol; 2003 Jul; 39(1):62-7. PubMed ID: 12821045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro.
    Mathews JM; Etheridge AS; Valentine JL; Black SR; Coleman DP; Patel P; So J; Burka LT
    Drug Metab Dispos; 2005 Oct; 33(10):1555-63. PubMed ID: 16033948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contaminant hepatotoxins as culprits for kava hepatotoxicity--fact or fiction?
    Teschke R; Sarris J; Lebot V
    Phytother Res; 2013 Mar; 27(3):472-4. PubMed ID: 22585547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kava's chemopreventive activity.
    Shaik AA; Hermanson DL; Xing C
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5732-6. PubMed ID: 19716299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herbal kava: reports of liver toxicity.
    Wooltorton E
    CMAJ; 2002 Mar; 166(6):777. PubMed ID: 11944767
    [No Abstract]   [Full Text] [Related]  

  • 36. Liver transplantation and the use of KAVA: Case report.
    Becker MW; Lourençone EMS; De Mello AF; Branco A; Filho EMR; Blatt CR; Mallmann CA; Schneider M; Caregnato RCA; Blatt CR
    Phytomedicine; 2019 Mar; 56():21-26. PubMed ID: 30668342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002.
    JAMA; 2003 Jan; 289(1):36-7. PubMed ID: 12515265
    [No Abstract]   [Full Text] [Related]  

  • 38. Kava-kava and anxiety: growing knowledge about the efficacy and safety.
    Bilia AR; Gallon S; Vincieri FF
    Life Sci; 2002 Apr; 70(22):2581-97. PubMed ID: 12269386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kava hepatotoxicity: regulatory data selection and causality assessment.
    Teschke R; Wolff A
    Dig Liver Dis; 2009 Dec; 41(12):891-901. PubMed ID: 19477698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers.
    Kanumuri SRR; Mamallapalli J; Nelson R; McCurdy CR; Mathews CA; Xing C; Sharma A
    J Ethnopharmacol; 2022 Oct; 297():115514. PubMed ID: 35777607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.